The US Food and Drug Administration's Puerto Rico district office "may be having difficulty exercising oversight on the numerous pharmaceutical manufacturing facilities on the island," according to Rep. Edolphus Towns (D-NY), chair of the US House of Representatives Committee on Oversight and Government Reform.
The US Food and Drug Administration’s Puerto Rico district office “may be having difficulty exercising oversight on the numerous pharmaceutical manufacturing facilities on the island,” according to Rep. Edolphus Towns (D-NY), chair of the US House of Representatives Committee on Oversight and Government Reform. Towns made this remark in a Nov. 8, 2010, letter, also signed by Rep. Darrell Issa (R-CA), to Margaret Hamburg, the agency’s commissioner.
Towns’s letter mentions the Committee’s follow-up hearing on the recall of infant, children, and adult over-the-counter products conducted by McNeil Consumer Healthcare, a subsidiary of Johnson and Johnson (New Brunswick, NJ). During the hearing, committee members of both major parties raised “still unanswered” questions about the involvement of employees at FDA’s district office in Puerto Rico, said Towns.
Other recent developments such as the US Department of Justice’s $750-million settlement with GlaxoSmithKline (GSK, London) have added to lawmakers’ concerns about the activities of FDA’s Puerto Rico office. Towns’s letter cites a New York Times article stating that GSK sold 20 drugs with “questionable safety” made at a large Puerto Rican plant “that for years was rife with contamination.” The article said that FDA’s inspectors in Puerto Rico observed some problems at the plant, but missed most of them. The story has prompted the Committee to question whether FDA’s Puerto Rico office is adequately staffed to ensure drug safety.
Towns asked Hamburg to provide the following information about the Puerto Rico district office by Nov. 17, 2010:
In addition to Johnson and Johnson and GSK, other pharmaceutical manufacturers recently have experienced problems relating to operations in Puerto Rico. This month, Pfizer (New York) recalled Lipitor tablets packaged at Rexam’s plant in Las Piedras. On Aug. 30, 2010, FDA sent Bristol-Myers Squibb (New York) a Warning Letter for failing to establish or follow rules to prevent contamination at its facility in Manati.
Letter:http://graphics8.nytimes.com/packages/pdf/business/20101108-DEI-Towns-Letter-to-FDA.pdf
Bristol-Myers Squibb:
http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm225277.htm
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.